SIC
PTGX icon

SJS Investment Consulting’s Protagonist Therapeutics PTGX Stock Holding History

SJS Investment Consulting’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491 Buy
+4
New +$418 ﹤0.01% 2277

Other funds holding PTGX

SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

SJS Investment Consulting's PTGX Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 4 shares worth $491. The stake represents ﹤0.01% of the portfolio and ranks #2277 among its holdings.

65 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • SJS Investment Consulting held 4 shares of Protagonist Therapeutics worth $491 as of Q2 2026.
  • Protagonist Therapeutics was a new SJS Investment Consulting position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2277 holding.
  • 65 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.